Cargando…
国产抗CD20单抗治疗CD20(+)B细胞非霍奇金淋巴瘤的Ⅰ期临床耐受性和药效学研究
OBJECTIVE: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin's lymphoma (NHL). METHODS: Nine patients with CD20(+) B-cell NHL received dose-escalating IBI301 infusio...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342123/ https://www.ncbi.nlm.nih.gov/pubmed/29779330 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.04.013 |